Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers
Mass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and system...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/9/8/931 |
| _version_ | 1797521897747906560 |
|---|---|
| author | Yu-Mi Wi Si-Ho Kim Kyong-Ran Peck |
| author_facet | Yu-Mi Wi Si-Ho Kim Kyong-Ran Peck |
| author_sort | Yu-Mi Wi |
| collection | DOAJ |
| description | Mass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and systemic reactions for 7 days after each dose, respectively. A total of 80 and 1440 healthcare workers received two doses of BNT162b2 and a first dose of AZD1222 vaccines. Any AEs were reported by 52.5% of recipients after the first dose of BNT162b2, by 76.2% after the second dose of BNT162b2, and by 90.9% after the first dose of AZD1222 (<i>p</i> < 0.001). Younger vaccinees had more AEs after the second dose of BNT162b2 and first dose of AZD1222. Sex based differences were only observed in the AZD1222 recipient group. No incidence of anaphylaxis or neurologic AEs were observed. In conclusion, early AEs were mostly mild to moderate in severity and generally transient in both BNT162b2 and AZD1222 groups. Sufficient explanation of the expected AEs of the vaccine would be helpful for wider vaccination. |
| first_indexed | 2024-03-10T08:19:01Z |
| format | Article |
| id | doaj.art-dc2abf112d184ca29f64cdab7cb1d2ff |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T08:19:01Z |
| publishDate | 2021-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-dc2abf112d184ca29f64cdab7cb1d2ff2023-11-22T10:08:12ZengMDPI AGVaccines2076-393X2021-08-019893110.3390/vaccines9080931Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare WorkersYu-Mi Wi0Si-Ho Kim1Kyong-Ran Peck2Division of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University, Changwon 51353, KoreaDivision of Infectious Diseases, Samsung Changwon Hospital, Sungkyunkwan University, Changwon 51353, KoreaDivision of Infectious Diseases, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, KoreaMass vaccination campaigns are important to control the COVID-19 pandemic, however, adverse events (AEs) contribute to vaccine hesitancy. To investigate and compare early AEs between the BNT162b2 mRNA and AZD1222 adenovirus-vectored vaccines, recipients completed daily surveys about local and systemic reactions for 7 days after each dose, respectively. A total of 80 and 1440 healthcare workers received two doses of BNT162b2 and a first dose of AZD1222 vaccines. Any AEs were reported by 52.5% of recipients after the first dose of BNT162b2, by 76.2% after the second dose of BNT162b2, and by 90.9% after the first dose of AZD1222 (<i>p</i> < 0.001). Younger vaccinees had more AEs after the second dose of BNT162b2 and first dose of AZD1222. Sex based differences were only observed in the AZD1222 recipient group. No incidence of anaphylaxis or neurologic AEs were observed. In conclusion, early AEs were mostly mild to moderate in severity and generally transient in both BNT162b2 and AZD1222 groups. Sufficient explanation of the expected AEs of the vaccine would be helpful for wider vaccination.https://www.mdpi.com/2076-393X/9/8/931coronavirus disease 2019vaccineadverse eventBNT162b2 mRNA vaccineAZD1222 vaccines |
| spellingShingle | Yu-Mi Wi Si-Ho Kim Kyong-Ran Peck Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers Vaccines coronavirus disease 2019 vaccine adverse event BNT162b2 mRNA vaccine AZD1222 vaccines |
| title | Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers |
| title_full | Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers |
| title_fullStr | Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers |
| title_full_unstemmed | Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers |
| title_short | Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers |
| title_sort | early adverse events between mrna and adenovirus vectored covid 19 vaccines in healthcare workers |
| topic | coronavirus disease 2019 vaccine adverse event BNT162b2 mRNA vaccine AZD1222 vaccines |
| url | https://www.mdpi.com/2076-393X/9/8/931 |
| work_keys_str_mv | AT yumiwi earlyadverseeventsbetweenmrnaandadenovirusvectoredcovid19vaccinesinhealthcareworkers AT sihokim earlyadverseeventsbetweenmrnaandadenovirusvectoredcovid19vaccinesinhealthcareworkers AT kyongranpeck earlyadverseeventsbetweenmrnaandadenovirusvectoredcovid19vaccinesinhealthcareworkers |